Macrocure logo

MCUR - Macrocure News Story

$1.51 0.0  0.0%

Last Trade - 20/01/17

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 7277

BRIEF-Macrocure says phase III clinical trial of Curexcell(R) in diabetic foot ulcers did not meet primary endpoint

Tue 27th October, 2015 9:20pm
Oct 27 (Reuters) - Macrocure Ltd  MCUR.O : 
 * Announces results for phase III clinical trial of Curexcell(R) in diabetic 
   foot ulcers and provides corporate update 
 * Results from a pivotal phase 3 study of curexcell in the treatment of 
   diabetic foot ulcers did not meet its primary endpoint 
 * In addition, curexcell did not meet the secondary endpoints of the study 
 
* Source text for Eikon  urn:newsml:reuters.com:*:nGNXVESAKa 
 
* Further company coverage  MCUR.O  ((Bengaluru Newsroom; +1 646 223 8780))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.